Abstract
Antibodies are invaluable macromolecules effectively utilized as detection reagents and therapeutics. Traditionally, researchers have relied upon the entire immunoglobulin molecule, however advances in protein engineering have ushered the use of antibody fragments as equally important biological tools such that at present, the downstream application generally dictates the antibody format employed. We provide herein robust and proven protocols for the isolation of autonomous human antibody variable heavy domains (VH). The strategy utilizes combinatorial phage-displayed libraries targeting human VH domain positions previously shown to promote autonomous behavior, and selection against a specified antigen. Subsequently, autonomous VH domains are characterized and chosen using standard biophysical methods.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Padlan EA (1994) Anatomy of the antibody molecule. Mol Immunol 31:169–217
Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544–546
Saerens D, Ghassabeh GH, Muyldermans S (2008) Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 8:600–608
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446–448
Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K et al (2002) Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98:456–462
Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S et al (1999) A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7:361–370
Desmyter A, Decanniere K, Muyldermans S, Wyns L (2001) Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem 276:26285–26290
Desmyter A, Spinelli S, Payan F, Lauwereys M, Wyns L et al (2002) Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem 277:23645–23650
Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F et al (1996) Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 3:803–811
Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W et al (1996) The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3:752–757
Spinelli S, Frenken LG, Hermans P, Verrips T, Brown K et al (2000) Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 39:1217–1222
Spinelli S, Tegoni M, Frenken L, van Vliet C, Cambillau C (2001) Lateral recognition of a dye hapten by a llama VHH domain. J Mol Biol 311:123–129
Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG et al (2000) Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol 37:579–590
Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484–490
Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 26:230–235
Nguyen VK, Hamers R, Wyns L, Muyldermans S (2000) Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J 19:921–930
Davies J, Riechmann L (1994) ‘Camelising’ human antibody fragments: NMR studies on VH domains. FEBS Lett 339:285–290
Howard GC, Kaser MR (2007) Making and using antibodies: a practical handbook. CRC Press/Taylor & Francis, Boca Raton, FL, p 394
Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS et al (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340:1073–1093
Sidhu SS, Weiss GA, Wells JA (2000) High copy display of large proteins on phage for functional selections. J Mol Biol 296:487–495
Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P et al (2008) Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem 283:3639–3654
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285–4289
Tokunaga E, Oki E, Nishida K, Koga T, Egashira A et al (2006) Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 11:199–208
Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G et al (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37:D1006–D1012
Jespers L, Schon O, James LC, Veprintsev D, Winter G (2004) Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J Mol Biol 337:893–903
Sidhu SS (2005) Phage display in biotechnology and drug discovery. Boca Raton: Taylor & Francis, xviii, p 748
Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A 101:12467–12472
Kunkel TA, Roberts JD, Zakour RA (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 154:367–382
Sidhu SS, Lowman HB, Cunningham BC, Wells JA (2000) Phage display for selection of novel binding peptides. Methods Enzymol 328:333–363
Bond CJ, Marsters JC, Sidhu SS (2003) Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries. J Mol Biol 332:643–655
Bond CJ, Wiesmann C, Marsters JC Jr, Sidhu SS (2005) A structure-based database of antibody variable domain diversity. J Mol Biol 348:699–709
de Wildt RM, Mundy CR, Gorick BD, Tomlinson IM (2000) Antibody arrays for high-throughput screening of antibody-antigen interactions. Nat Biotechnol 18:989–994
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Greenfield NJ (2006) Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nat Protoc 1:2527–2535
Kabat EA, Wu TT, Reid-Miller M, Perry H, Gottesman K (1987) Sequence of proteins of immunological interest. National Institutes of Health Research, Bethesda, p 2387
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Tonikian, R., Sidhu, S.S. (2012). Selecting and Purifying Autonomous Human Variable Heavy (VH) Domains. In: Saerens, D., Muyldermans, S. (eds) Single Domain Antibodies. Methods in Molecular Biology, vol 911. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-968-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-61779-968-6_20
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-967-9
Online ISBN: 978-1-61779-968-6
eBook Packages: Springer Protocols